Optimizing Postprandial Glycemic Management: Prandial Insulin, Continuous Glucose Monitoring, and Improved Self-care Engagement
Released On
May 30, 2023
Expires On
May 30, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Endocrinology
Topic(s)
Diabetes
Presented by Joslin Diabetes Center in Joint Providership with PlatformQ Health Education, LLC.
This activity is supported by an educational grant from MannKind Corporation.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
The primary target audience for this activity are primary care physicians, endocrinologists, NPs, and PAs. The secondary target audience for this activity are pharmacists and certified diabetes care and education specialists.
Program Overview
Patients with type 1 diabetes (T1DM) and some patients with type 2 diabetes require daily administration of exogenous insulin to maintain blood-glucose levels within the normal range both pre‐ and post‐prandially. There are a wide variety of insulin products, delivery methods, and monitoring devices to help people achieve these goals. To develop an optimal, individualized management strategy and to adjust treatment regimens based on continuous glucose monitoring, clinicians need to understand the spectrum of insulins available, including their efficacy, safety, indications, and usage parameters.
Join a panel of experts, including a moderator from Joslin Diabetes Center and two clinicians with expertise in diabetes, to review the indications for and role of exogenous prandial insulin treatment to achieve glucose control in people with T1DM and others requiring insulin-replacement therapy. Clinicians will learn to interpret results from a continuous glucose monitor and use them to determine and titrate insulin‐replacement programs. Panelists will also share strategies to encourage shared decision‐making and provide patient education, motivation, and access to diabetes self‐management support.
Educational Objectives
At the conclusion of this activity, participants will be able to:
- Discuss the indications for and role of exogenous prandial insulin treatment in maintaining glucose control in people with T1DM and others requiring physiologic insulin‐ replacement therapy
- Interpret the results from a continuous glucose monitor and use those results to determine and titrate insulin‐ replacement programs
- Select strategies for shared decision‐making to select insulin types, treatment designs, and use of continuous glucose monitoring technology with patients who require insulin therapy
Faculty
Dr. Richard S. Beaser*†
Senior Staff Physician and Medical Director of CME
Joslin Diabetes Center
Associate Professor of Medicine
Harvard Medical School
Richard Pratley, MD
AdventHealth
Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute
Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
Alissa Segal, PharmD, RPh, CDCES, CDTC†
Professor of Pharmacy Practice, Massachusetts College of Pharmacy & Health Sciences
Clinical Pharmacist, Joslin Diabetes Center
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Joslin Diabetes Center and PlatformQ Health Education, LLC. Joslin Diabetes Center is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Joslin Diabetes Center designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
As part of its accreditation with the Accreditation Council for Continuing Medical Education, Joslin Diabetes Center must disclose to the audience of a Joslin continuing medical education activity the existence of any relevant financial relationships between Joslin and/or its planning and/or CME advisory committee members, speakers, and their spouses/partners and commercial entities. Joslin and its planning and CME advisory committee members and speakers must disclose any relationships they and their spouses/partners have or have had in the prior 12 months with proprietary entities producing healthcare goods or services, with the exception of nonprofit or government organizations and non-healthcare-related companies, which are exempt.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fees, honoraria, ownership interests (e.g., stocks, stock options, or other ownership interest, excluding diversified mutual funds), or other financial benefit in any amount. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
If a faculty or planning committee member has no information to disclose, this information will also be provided. If a faculty or planning committee member refuses to disclose, he/she will not be able to participate in the planning, management, presentation, or evaluation of any Joslin Diabetes Center CME activity. In addition, faculty have been asked to disclose when a product or device is not labeled for the use under discussion. The opinions and comments expressed in this program are those of the speakers and should not be considered the opinions or comments of Joslin Diabetes Center.
The planners and faculty have reported the following financial relationships with commercial interests. Via Joslin internal review, any relationship deemed relevant to the content of this activity has been identified and resolved through Joslin’s internal processes.
The faculty and planning committee members for this program have disclosed the following:
Faculty
- Dr. Richard S. Beaser*†
- has no relevant financial relationships with regard to this activity
- Richard Pratley, MD
- Grant/research support: Novo Nordisk
- Academic Consultant : Bayer AG, Gasherbrum Bio, Inc., Hengrui (USA) Ltd., Merck, Novo Nordisk, Rivus Pharmaceuticals Inc., and Sun Pharmaceutical Industries
- Alissa Segal, PharmD, RPh, CDCES, CDTC†
- has no relevant financial relationships with regard to this activity
Planning Committee
- Terry Glauser, MD, Medical Director, PlatformQ Health Education
- has no relevant financial relationships with regard to this activity
- Jaimee Harris-Gold, Program Manager, PlatformQ Health Education
- has no relevant financial relationships with regard to this activity
Joslin CME Advisory Committee
- Jerry Cavallerano, OD, Optometrist, Beetham Eye Institute, Joslin Diabetes Center
- has no relevant financial relationships with regard to this activity
- Erin Kelly, M.Ed., RN, BSN, CDE, Adult Diabetes Educator, Joslin Diabetes Center
- Stockholder: Tandem Diabetes Care
- Lyle Mitzner, MD, Staff Physician, Joslin Diabetes Center
- Consultant: Conversa Health
- Robert C. Stanton, MD, Chief of Nephrology, Joslin Diabetes Center
- has no relevant financial relationships with regard to this activity
- Elena Toschi, MD, Staff Physician, Joslin Diabetes Center
- has no relevant financial relationships with regard to this activity
* Also on the Planning Committee
† Also on the CME Advisory Committee
Instructions for Participation and Credit
Estimated time to Complete
This activity should take approximately 1 hour to complete
Method of Participation
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must (1)read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that these modules will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
Certificates will be emailed to the participant.
Course Viewing Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclaimer
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Joslin Diabetes Center, DiabetesSeriesLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Contact Information
Please send content inquiries to: cme@joslin.harvard.edu.
For technical problems with the site or issues with your CME Certificate, please contact DiabetesSeriesLive at 877-394-1306 or at Support@DiabetesSeriesLive.com.
PlatformQ Health Privacy Policy
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor do we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/